Improving the efficacy of liposome-mediated vascular gene therapy via lipid surface modifications (2017)
Sequence: RRRRRRRR
| Experiment Id | EXP001434 |
|---|---|
| Paper | Improving the efficacy of liposome-mediated vascular gene therapy via lipid surface modifications |
| Peptide | Octaarginine (R8) |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | |
| Endosomal Escape Evidence | |
| Peptide Concentration | Surface density: 5 mol% STR-R8 of total lipids |
| Rna Concentration | Encapsulated siRNA; cell studies used equal lipid/siRNA loads; cytotoxicity & transfection comparisons at 200 nM siRNA (HASMCs) |
| Mixing Ratio | For assembly: 125–1000 µg total lipid with 50 µg siRNA; subsequent experiments controlled by lipid/siRNA dose; CaCl2 10 mM used for neutral formulations |
| Formulation Format | R8-modified PEGylated neutral liposomes (R8-PLP) |
| Formulation Components | Neutral PEGylated liposome (PLP) base: DOPC:cholesterol 7:3 mol + 10 mol% DSPE-PEG2000 + STR-R8 (5 mol%) + encapsulated siRNA |
| Size Nm | 35.90 |
| Zeta Mv | 8.80 |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | Human aortic smooth muscle cells (HASMCs, primary; 49-year-old male donor) |
| Animal Model | |
| Administration Route | |
| Output Type | Cell association (rhodamine-labeled liposomes; fluorometry) and cytotoxicity (LIVE/DEAD stain) |
| Output Value | |
| Output Units | |
| Output Notes | R8-PLP 5 mol% increased cell association vs nonmodified PLP and showed no significant cytotoxicity vs untreated controls. |
| Toxicity Notes | No significant cytotoxicity detected at 200 nM siRNA exposure (LIVE/DEAD assay). |
| Curation Notes |